The drug efflux-metabolism alliance: biochemical aspects.
about
Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugsMembrane transporters in drug developmentClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!Functional interactions between P-glycoprotein and CYP3A in drug metabolism.A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.Clinical studies with oral lipid based formulations of poorly soluble compoundsPharmacokinetic strategies in deciphering atypical drug absorption profiles.Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.Importance of P-glycoprotein for drug disposition in humans.Clinical relevance of P-glycoprotein in drug therapy.Immunological response as a source to variability in drug metabolism and transport.The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance.Pharmacokinetic principles of immunosuppressive drugs.Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player?Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.Natural polyphenol disposition via coupled metabolic pathways.Intestinal permeability and its relevance for absorption and elimination.Modeling kinetics of subcellular disposition of chemicals.Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant.Tacrolimus interaction with clotrimazole: a concise case report and literature review.Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.Current understanding of drug disposition in kidney disease.Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS).Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Loss of orally administered drugs in GI tract.In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.Formulation strategies to improve oral peptide delivery.Review article: The nutritional and pharmacological consequences of obesity surgery.Vitamin E-drug interactions: molecular basis and clinical relevance.The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Intestinal drug transporter expression and the impact of grapefruit juice in humans.Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.Pharmacokinetic interaction of some antitubercular drugs with caraway: implications in the enhancement of drug bioavailability.
P2860
Q26774831-737D74EE-A80F-4B84-AAD7-9299FAE799CBQ29616802-4DDE2F75-5A27-457E-B701-8A9356B0B0A8Q30234940-98154889-C5EF-4879-8580-C3114DB9C4E1Q33696563-0826542A-9B43-40EE-B6E5-5D8E22D26E55Q34171741-E3EE1C49-4AE4-430B-8395-58D69770D230Q34190195-F41C0470-9032-4251-A323-935D9CEC1C82Q34289184-61937C76-CDCB-4EB0-B64B-5097EC7D4B50Q34550483-2659A4AC-9778-4C9D-B4E9-CAF121475833Q34665881-5D9F9DF4-18E0-4E77-8DB7-D9D5E4E29678Q34778043-E77022F3-60E6-435D-BF7A-5E5E1B6B4E17Q35085676-2777164D-94BE-43A1-AD1B-3BB0CBC7B33EQ35557449-483183DD-0142-4471-A35F-3E38AF176A45Q35594556-8F34773B-76DB-411A-8B59-EA9C4D343B61Q35620664-8E7F5092-F3F8-4D0E-B925-4DA445C8AB14Q35749503-A8D7353D-1E4F-41F6-8B75-08EBFEBD9B42Q35956193-E4FBE4B3-E2A9-4EA8-A1E6-F083A30FD72AQ36006086-4B61C2EF-758C-485C-BDAA-CF464E28C6F2Q36292830-517B0422-5FB5-44DF-AA49-356069110E5DQ36390234-A0DCE0EB-AAA1-47F9-B7D2-E00F3483EC69Q36835822-9ABF7721-D1ED-4EBE-BFEF-DDAEBBA77BECQ36985043-B0C5DE9A-A54E-4E5A-BEE8-8AE70B2619EDQ37194304-F8A6C2C9-0371-4828-B7F8-5D93A05FFA80Q37772515-DD4E435E-6A7E-49BF-A1DE-8261A8081755Q37805337-46112853-0861-436E-83DC-81DE1C2F92B8Q37964574-FDAB20F1-24D0-4A60-B880-75AF404FF63DQ37974644-1E79961B-465B-47A0-B11A-0CB18F1E319CQ37988960-DB3604E3-08AA-4A3A-B34A-90EACFA2731AQ38082728-D6556A3D-51B8-4F79-A041-5B93BCE161CCQ38130231-4BE7ABAC-0DF7-4D40-B023-09134F37A6DEQ38131859-E4B496F7-347B-4556-A93D-FE7CB2AFD466Q38226675-2F71A209-056E-4FFF-BEE1-CCA908FEA2E5Q38235543-AA1D2495-4160-4C93-A184-C68AC7E1C01EQ38250082-E1919718-DFF6-4E07-853B-6D860F58CC74Q38844656-87ED04B7-A1BA-48E8-8B2F-B88587F25DA0Q40184411-C0E8A4FA-D7E1-4464-B8C1-9D03B2BB1DB5Q40929413-16B57DFE-A0AC-4DDE-B01C-318F886367E0Q41107618-E017E5CE-3A5A-451D-9371-CDF03D258495Q42429561-CC3C81A6-5B18-424C-9BF4-24EA5099B543Q42717938-D74805AB-A5FF-4FBF-9A7A-7CAA200D2AEEQ43280262-B49813B6-6020-40C7-90F4-36138686B12F
P2860
The drug efflux-metabolism alliance: biochemical aspects.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The drug efflux-metabolism alliance: biochemical aspects.
@ast
The drug efflux-metabolism alliance: biochemical aspects.
@en
The drug efflux-metabolism alliance: biochemical aspects.
@nl
type
label
The drug efflux-metabolism alliance: biochemical aspects.
@ast
The drug efflux-metabolism alliance: biochemical aspects.
@en
The drug efflux-metabolism alliance: biochemical aspects.
@nl
prefLabel
The drug efflux-metabolism alliance: biochemical aspects.
@ast
The drug efflux-metabolism alliance: biochemical aspects.
@en
The drug efflux-metabolism alliance: biochemical aspects.
@nl
P1476
The drug efflux-metabolism alliance: biochemical aspects
@en
P2093
P356
10.1016/S0169-409X(01)00178-8
P407
P478
50 Suppl 1
P577
2001-10-01T00:00:00Z